THERAMEX
17.6.2022 12:45:04 CEST | Business Wire | Press release
The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age. This announcement is in partnership with ObsEva SA (Nasdaq: OBSV), a biopharmaceutical company developing and commercializing novel therapies for women’s health.
The EC decision follows the Committee for Medicinal Products for Human Use (CHMP) confirmation of positive opinion in April 2022.
Linzagolix ® is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF. Yselty® is approved in the EU at the following doses:
- 100 mg or 200 mg once daily with hormonal ABT, with no limitation in treatment duration
- 100 mg once daily for women in whom ABT is not recommended or who prefer to avoid hormonal therapy, with no limitation in treatment duration
- 200 mg once daily for short-term use (< 6 months) in clinical situations when reduction of uterine and fibroid volume is desired
The approval is based on positive data from the ObsEva’s two Phase 3 PRIMROSE trials.
“Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery. With the approval of Linzagolix we can potentially offer a new treatment option for physicians in managing women with uterine fibroids to provide symptomatic relief and delay or avoid surgery. Additionally, we will continue to work with our partner ObsEva for follow-on indications, such as endometriosis, another area of women’s health with limited treatment options. This marks an important therapeutic extension for Theramex to widen our portfolio and provide gynaecologist’s support for unmet medical needs,” said Robert Stewart, Theramex CEO.
“As the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy, Yselty® has the potential to transform the treatment paradigm and significantly advance medical options for women in the EU with uterine fibroids,” said Dr. Brandi Howard, Chief Clinical Officer of ObsEva. “We are pleased to be the first to provide women and doctors with a non-hormonal dosing option for the millions of women who either have contraindications to or a personal preference to avoid the use of hormonal add-back therapy, while also providing dosing options for women for whom hormonal add-back therapy is appropriate.”
In February 2022, Theramex entered into a strategic licensing agreement with Obseva, a leading biopharmaceutical company in novel therapies, to commercialize and market the introduction of linzagolix across international markets outside of the U.S., Canada, and Asia.
About Yselty® (linzagolix)
Linzagolix is a once daily, oral GnRH receptor antagonist developed to offer flexible dosing options with and without hormonal add-back therapy to women suffering from uterine fibroids and is approved in the EU.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Theramex’s commitment is to listen to and understand its patients, serve their needs and offer healthcare solutions to help improve their lives. Theramex’s vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through different stages of their life.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to help improve women’s reproductive health and pregnancy. The Company’s first approved drug is Yselty® (linzagolix), which is approved in the EU. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”.
For more information, please visit www.ObsEva.com
About Kissei
Linzagolix has been discovered by Central Research Laboratories of Kissei Pharmaceutical Co., Ltd. Kissei is a Japanese pharmaceutical company based on the management philosophy “contributing to society through high-quality, innovative pharmaceutical products” and “serving society through our employees.” As a strong R&D-oriented corporation, it concentrates on providing innovative pharmaceuticals to patients worldwide in the focus fields of urology, nephrology/dialysis, gynaecology and rare/intractable diseases.
Yselty_HQ_PRESSR_007649 D.O.P: 17/06/22
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005176/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Grupo Salinas Selects Integral Digital to Power Coinpro’s Institutional Digital Asset Trading Desk3.9.2026 17:01:00 CEST | Press release
COINPRO will use Integral’s technology to aggregate liquidity, automate pricing and support wholesale transactions between digital assets and fiat currencies Integral, a leading currency technology provider, today announced that Grupo Salinas, through COINPRO, has selected Integral Digital as the technology infrastructure for Coinpro’s institutional digital asset trading desk. The desk is designed to serve corporate and institutional clients seeking to buy or sell digital assets against fiat currencies. Its wholesale model will support exchanges, digital asset companies and other businesses that require institutional pricing, liquidity and execution. Integral Digital will provide Coinpro with a single environment for liquidity aggregation, price formation, order and position management, risk controls and real-time analytics across digital assets and fiat currencies. By automating these functions, Coinpro will be able to quote and execute institutional transactions more efficiently and
Energy Vault Accelerates 125 MW / 1 GWh Stoney Creek BESS Toward Construction with Full Project Land Acquisition Milestone in Australia3.9.2026 16:40:00 CEST | Press release
Energy Vault completes acquisition of the underlying project land following FIRB government approval, converting from existing lease agreement to full land ownership, advancing construction readiness for the 125 MW / 1 GWh Stoney Creek BESSConstruction now expected to commence in Q1 2027, with commercial operations targeted for H1 2028; the project is supported by a 14-year Long-Term Energy Service Agreement (LTESA), providing expected annual, long-term revenue of approximately $25-$30 million per year Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault” or the “Company”), a global energy infrastructure company supporting grid reliability and next-generation AI and high-performance computing infrastructure, today announced the completion of the acquisition of the underlying project land for the 125 MW / 1 GWh Stoney Creek Battery Energy Storage System (“BESS”) in Northern New South Wales, Australia. The land, which was previously secured under an agreement for lease, is now owned b
The Estée Lauder Companies Announces Brand Leadership Appointments3.9.2026 16:37:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced several brand leadership appointments following the upcoming retirement of Sandra Main, Global Brand President, La Mer and Skin Care Brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902005552/en/ Justin Boxford, Global President, Luxury Beauty Brands, Erica Kwok, Senior Vice President and General Manager of Estée Lauder, and Magalie Parksuwan, Senior Vice President and General Manager, La Mer Justin Boxford will assume the newly established role of Global President, Luxury Beauty Brands, expanding his portfolio to include La Mer alongside Estée Lauder, AERIN, Darphin Paris and Lab Series. Justin brings extensive experience with La Mer, having led the brand from 2017 to 2022 before assuming leadership of Estée Lauder. During his tenure, he expanded and diversified La Mer’s product portfolio, strengthened its luxury architecture and advanced the brand’s presen
HTEC Momentum Extends Award-Winning UX Track Record with Two UX Design Awards Honors3.9.2026 14:18:00 CEST | Press release
HTEC Momentum, the product and design practice within HTEC Group, has earned honors at the UX Design Awards 2026 for its work with Zingtree and the National Society Daughters of the American Revolution (DAR). Presented by the International Design Center Berlin (IDZ), the global competition celebrates excellence in user experience design across industries, with the 2026 shortlist including 195 projects across 46 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903181166/en/ HTEC Momentum, the product and design practice within HTEC Group, has earned honors at the UX Design Awards 2026 for its work with Zingtree and the National Society Daughters of the American Revolution (DAR). Presented by the International Design Center Berlin (IDZ), the global competition celebrates excellence in user experience design across industries, with the 2026 shortlist including 195 projects across 46 countries. Honored in the product
Former SADA Executive Lusine Yeghiazaryan Joins Picsart as CFO to Drive AI-Native Video Growth Strategy3.9.2026 14:00:00 CEST | Press release
Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903569581/en/ Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. Yeghiazaryan joins Picsart at a pivotal chapter in its evolution, as the company expands beyond its roots as a leading creative platform to build a video-first, AI-powered production ecosystem. Already in motion, Picsart users created over 1.1B AI videos and images since launch, with YTD AI usage up 270% year over year - underscoring the company’s accelerating push to capture a larger share of the fast-growing AI content m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
